N-methylvaline : An N-methylamino acid that is the N-methyl derivative of valine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 4378 |
| CHEBI ID | 64348 |
| SCHEMBL ID | 43660 |
| MeSH ID | M0443736 |
| Synonym |
|---|
| nsc-89800 |
| nsc89800 |
| NCIOPEN2_001562 |
| n-methylvaline |
| n-methyl-dl-valine |
| 2566-32-7 |
| 3-methyl-2-(methylamino)butanoic acid |
| STL262623 |
| AKOS009209167 |
| CHEBI:64348 |
| meval |
| (s/r)-n-methylvaline |
| FT-0634369 |
| FT-0634311 |
| n-methylvaline hydrochloride |
| SCHEMBL43660 |
| n-methylvaline # |
| AKCRVYNORCOYQT-UHFFFAOYSA-N |
| 2-methylamino-3-methylbutanoic acid |
| FT-0699154 |
| n-me-dl-val-oh |
| lna7qs6jb7 , |
| unii-lna7qs6jb7 |
| dl-n-methylvaline |
| dl-valine, n-methyl- |
| Q27133228 |
| CS-0201923 |
| noname_3444 |
| DTXSID20902870 |
| AS-57090 |
| EN300-149672 |
| HY-W142140 |
| Class | Description |
|---|---|
| valine derivative | An amino acid derivative resulting from reaction of valine at the amino group or the carboxy group, or from the replacement of any hydrogen of valine by a heteroatom. The definition normally excludes peptides containing valine residues. |
| N-methyl-amino acid | An amino acid derivative in which at least one of the hydrogens of the amino group has been replaced by a methyl group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.43) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||